Colgate-Palmolive (NYSE:CL) was downgraded by stock analysts at BNP Paribas from an “outperform” rating to an “underperform” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports.
Other research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $82.00 price objective on the stock in a research note on Monday, October 2nd. SunTrust Banks upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $65.00 to $85.00 in a research note on Wednesday, October 11th. KeyCorp restated a “hold” rating on shares of Colgate-Palmolive in a research note on Monday, October 16th. Royal Bank of Canada restated a “hold” rating and set a $74.00 price objective on shares of Colgate-Palmolive in a research note on Sunday, October 8th. Finally, Jefferies Group reduced their price objective on Colgate-Palmolive from $79.00 to $76.00 and set a “hold” rating on the stock in a research note on Monday, October 30th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have given a buy rating to the company’s stock. Colgate-Palmolive has an average rating of “Hold” and an average price target of $77.48.
Shares of Colgate-Palmolive (CL) traded up $0.88 during trading on Tuesday, reaching $74.67. The company had a trading volume of 6,027,481 shares, compared to its average volume of 3,500,000. Colgate-Palmolive has a 52-week low of $63.95 and a 52-week high of $77.91. The firm has a market capitalization of $65,570.00, a PE ratio of 32.75, a P/E/G ratio of 3.06 and a beta of 0.81. The company has a quick ratio of 0.34, a current ratio of 0.47 and a debt-to-equity ratio of 24.42.
In related news, insider Jennifer Daniels sold 902 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $75.82, for a total value of $68,389.64. Following the completion of the sale, the insider now directly owns 37,788 shares of the company’s stock, valued at $2,865,086.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Mukul Deoras sold 7,500 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $73.28, for a total value of $549,600.00. Following the completion of the sale, the chief marketing officer now directly owns 45,217 shares of the company’s stock, valued at $3,313,501.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 181,950 shares of company stock valued at $13,237,385. 1.02% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the stock. Blue Chip Partners Inc. boosted its stake in Colgate-Palmolive by 0.4% in the second quarter. Blue Chip Partners Inc. now owns 1,813 shares of the company’s stock valued at $134,000 after acquiring an additional 8 shares during the period. AlphaMark Advisors LLC boosted its stake in Colgate-Palmolive by 1.5% in the second quarter. AlphaMark Advisors LLC now owns 1,698 shares of the company’s stock valued at $126,000 after acquiring an additional 25 shares during the period. Weatherstone Capital Management boosted its stake in Colgate-Palmolive by 0.7% in the second quarter. Weatherstone Capital Management now owns 4,069 shares of the company’s stock valued at $302,000 after acquiring an additional 28 shares during the period. Dorsey & Whitney Trust CO LLC boosted its stake in Colgate-Palmolive by 0.6% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 5,642 shares of the company’s stock valued at $419,000 after acquiring an additional 34 shares during the period. Finally, Jackson Grant Investment Advisers Inc. boosted its stake in Colgate-Palmolive by 0.5% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 7,028 shares of the company’s stock valued at $521,000 after acquiring an additional 35 shares during the period. 72.96% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Colgate-Palmolive (CL) Cut to “Underperform” at BNP Paribas” was published by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/30/colgate-palmolive-cl-cut-to-underperform-at-bnp-paribas.html.
Colgate-Palmolive Company Profile
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
